

Special Issue

Risk Factors and Molecular Mechanisms in Diabetes and Cardiovascular Complications

Message from the Guest Editor

This Special Issue aims to focus on research on the intricate interplay between diabetes mellitus and cardiovascular diseases (CVDs). We welcome original research articles and comprehensive reviews that explore a wide spectrum of topics, from established and emerging risk factors to the complex molecular mechanisms underpinning the development and progression of cardiovascular complications in diabetic patients. Particular emphasis will be placed on studies investigating novel biomarkers (such as the triglyceride-glucose index), the role of insulin resistance, and genetic and epigenetic predispositions to CVD in the context of diabetes. Furthermore, contributions elucidating the molecular pathways, such as non-coding RNAs and cell death mechanisms like PANoptosis, that link diabetes to atherosclerosis, ischemic heart disease, and other cardiovascular pathologies are highly encouraged. The goal is to foster a deeper understanding and highlight potential new avenues for risk stratification, prevention, and therapeutic intervention at the intersection of these two prevalent and debilitating conditions.

Guest Editor

Dr. Xiao Liu

Department of Cardiology, Sun Yat-Sen Memorial Hospital, Guangzhou, China

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/243977

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).